400 related articles for article (PubMed ID: 19378390)
1. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N
J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390
[TBL] [Abstract][Full Text] [Related]
2. Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?
Hashimoto E; Farrell GC
J Gastroenterol Hepatol; 2009 Apr; 24(4):501-3. PubMed ID: 19368628
[No Abstract] [Full Text] [Related]
3. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
Tanwar S; Trembling PM; Guha IN; Parkes J; Kaye P; Burt AD; Ryder SD; Aithal GP; Day CP; Rosenberg WM
Hepatology; 2013 Jan; 57(1):103-11. PubMed ID: 22930399
[TBL] [Abstract][Full Text] [Related]
4. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
Younossi ZM; Page S; Rafiq N; Birerdinc A; Stepanova M; Hossain N; Afendy A; Younoszai Z; Goodman Z; Baranova A
Obes Surg; 2011 Apr; 21(4):431-9. PubMed ID: 20532833
[TBL] [Abstract][Full Text] [Related]
5. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
[TBL] [Abstract][Full Text] [Related]
7. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience.
Lee CK; Perez-Atayde AR; Mitchell PD; Raza R; Afdhal NH; Jonas MM
J Pediatr; 2013 Oct; 163(4):1058-64.e2. PubMed ID: 23759423
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.
Saitou Y; Shiraki K; Yamanaka Y; Yamaguchi Y; Kawakita T; Yamamoto N; Sugimoto K; Murata K; Nakano T
World J Gastroenterol; 2005 Jan; 11(4):476-81. PubMed ID: 15641129
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
[TBL] [Abstract][Full Text] [Related]
12. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M
Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489
[TBL] [Abstract][Full Text] [Related]
13. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD).
Raszeja-Wyszomirska J; Szymanik B; Ławniczak M; Kajor M; Chwist A; Milkiewicz P; Hartleb M
BMC Gastroenterol; 2010 Jun; 10():67. PubMed ID: 20584330
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.
Lebensztejn DM; Wierzbicka A; Socha P; Pronicki M; Skiba E; Werpachowska I; Kaczmarski M
Acta Biochim Pol; 2011; 58(4):563-6. PubMed ID: 22140659
[TBL] [Abstract][Full Text] [Related]
15. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection.
Schiavon LL; Carvalho-Filho RJ; Narciso-Schiavon JL; Medina-Pestana JO; Lanzoni VP; Ferraz ML; Silva AE
Scand J Gastroenterol; 2010 May; 45(5):615-22. PubMed ID: 20163287
[TBL] [Abstract][Full Text] [Related]
16. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.
Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V
Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877
[TBL] [Abstract][Full Text] [Related]
17. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.
Ekstedt M; Franzén LE; Mathiesen UL; Kechagias S
Scand J Gastroenterol; 2012 Jan; 47(1):108-15. PubMed ID: 22126450
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
19. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
[TBL] [Abstract][Full Text] [Related]
20. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
